Free tool
FAERS Monitor: Intralipid 20%
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 018449 or its brand name (Intralipid 20%, Soybean Oil). Reports on generic versions are filed under their own applications.
Reports
727
Serious
626
86% of reports
Hospitalization
249
Death reported
85
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- chills75
- pyrexia57
- parenteral nutrition associated liver disease56
- nausea53
- dyspnoea46
- vomiting45
- chest discomfort42
- diarrhoea39
- off label use35
- weight decreased35
- drug ineffective32
- product dose omission issue29
- decreased appetite28
- hyperpyrexia27
- hypotension24
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 4 |
| 2005 | 1 |
| 2012 | 6 |
| 2013 | 27 |
| 2014 | 49 |
| 2015 | 67 |
| 2016 | 78 |
| 2017 | 65 |
| 2018 | 52 |
| 2019 | 50 |
| 2020 | 44 |
| 2021 | 53 |
| 2022 | 51 |
| 2023 | 60 |
| 2024 | 58 |
| 2025 | 32 |
| 2026 | 29 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,432 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| parenteral nutrition associated liver diseaseSignal | 56 | 49143.1 | 32162.3 | 1,002,232 |
| hyperpyrexiaSignal | 27 | 185.7 | 128.1 | 4,747 |
| chillsSignal | 75 | 18.5 | 14.9 | 1,232 |
| chest discomfortSignal | 42 | 11.9 | 8.9 | 409 |
| pyrexiaSignal | 57 | 4.8 | 3.7 | 169 |
| weight decreasedSignal | 35 | 3.6 | 2.6 | 65 |
| decreased appetiteSignal | 28 | 3.5 | 2.4 | 48 |
| hypotensionSignal | 24 | 3.5 | 2.3 | 40 |
| product dose omission issueSignal | 29 | 2.9 | 2.0 | 34 |
| vomitingSignal | 45 | 2.8 | 2.1 | 50 |
| dyspnoeaSignal | 46 | 2.4 | 1.8 | 35 |
| nausea | 53 | 1.9 | 1.5 | 24 |
| diarrhoea | 39 | 1.7 | 1.3 | 12 |
| off label use | 35 | 1.2 | 0.8 | 1 |
| drug ineffective | 32 | 0.7 | 0.5 | 4 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.